Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Preparation and In Vitro and In Vivo Antitumor Effects of VEGF Targeting Micelles.

Authors:
Jing Chang Zhe Yang Junfeng Li Yufen Jin Yihang Gao Yanwen Sun Hainan Li Ting Yu

Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820957022

154454The Second Hospital of Jilin University, Nanguan District, Changchun, China.

Background: Doxorubicin (DOX) has antitumor effects mediated by cell viability inhibition and by inducing cellular apoptosis. However, it has limited use in clinical applications due to various factors such as hydrophobicity, dose-dependent toxicity effects on normal tissues, short cycle retention time, and low targeting ability. This study aims at enhancing hydrophilicity of DOX to restrict its toxic effects to within or around the tumor sites and also to improve its targeting ability to enhance antitumor efficiency.

Methods: Micelles composed of biodegradable poly (ethylene glycol)-poly (lactic acid) copolymers (PEG-PLA) were employed to deliver DOX via a self-assembly method and were coupled to VEGF antibodies. The morphology, size, and physical stability of PEG-PLA-DOX targeting VEGF micelles (VEGF-PEG-PLA-DOX micelles) were assessed. Then, the release ability of DOX from these micelles was monitored, and their drug loading capacity was calculated. MTT assay revealed the antitumor effect of VEGF-PEG-PLA-DOX micelles. Moreover, ROS release was measured to evaluate apoptotic effects of these nanoparticle micelles. therapeutic efficiencies of VEGF-PEG-PLA-DOX micelles on a lung cancer nude mouse model was evaluated.

Results: DOX-loaded micelles were obtained with a drug loading capacity of 12.2% and were monodisperse with 220 nm average diameter and a controlled DOX release for extended periods. In addition, VEGF-PEG-PLA-DOX micelles displayed a larger cell viability inhibitory effect as measured via MTT assays and greater cell apoptosis induction through ROS levels compared with PEG-PLA-DOX micelles or free DOX. Furthermore, VEGF-PEG-PLA-DOX micelles could improve antitumor effects of DOX by reducing tumor volume and weight.

Conclusions: VEGF-PEG-PLA-DOX micelles displayed a larger anti-tumor effect both in A549 cells and in an lung cancer nude mouse model compared with PEG-PLA-DOX micelles or free DOX, and hence they have potential clinical applications in human lung cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533033820957022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488921PMC
September 2020

Publication Analysis

Top Keywords

vegf-peg-pla-dox micelles
24
micelles
14
antitumor effects
12
lung cancer
12
cancer nude
8
displayed larger
8
nude mouse
8
micelles displayed
8
dox
8
peg-pla-dox micelles
8
compared peg-pla-dox
8
mouse model
8
cell viability
8
free dox
8
clinical applications
8
loading capacity
8
targeting ability
8
drug loading
8
micelles free
8
effects
6

Keyword Occurance

Similar Publications

Preparation and In Vitro and In Vivo Antitumor Effects of VEGF Targeting Micelles.

Authors:
Jing Chang Zhe Yang Junfeng Li Yufen Jin Yihang Gao Yanwen Sun Hainan Li Ting Yu

Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820957022

154454The Second Hospital of Jilin University, Nanguan District, Changchun, China.

Background: Doxorubicin (DOX) has antitumor effects mediated by cell viability inhibition and by inducing cellular apoptosis. However, it has limited use in clinical applications due to various factors such as hydrophobicity, dose-dependent toxicity effects on normal tissues, short cycle retention time, and low targeting ability. This study aims at enhancing hydrophilicity of DOX to restrict its toxic effects to within or around the tumor sites and also to improve its targeting ability to enhance antitumor efficiency. Read More

View Article and Full-Text PDF
September 2020
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap